NON-SMALL CELL LUNG CANCER

This early-phase trial tests whether adding the cholesterol drug pitavastatin to standard chemotherapy can shrink tumors in people with advanced non-small cell lung cancer that no longer responds to second-line treatment. A lab test using patient-derived tumor-like cell clusters …

This study tests a new drug (ANS014004) combined with a standard targeted therapy (EGFR-TKI) in people with advanced EGFR-mutated non-small cell lung cancer. The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing, especially when th…

This study tests a new immunotherapy drug (QL1706) combined with chemotherapy and a special type of radiation (quad shot) in people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if adding radiation improves tumor shrinkage and delay…

This study tests two drug combinations for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC). One group gets a new drug combo as their first treatment, and another group gets it after their current treatment stops working. The goal is to see how the drugs af…

This pilot study looks at whether it is safe and feasible to skip surgery in patients with stage II-III non-small cell lung cancer whose tumors completely disappear after chemotherapy and immunotherapy. Fourteen participants will be randomly assigned to either standard surgery or…

This study tests a new drug called JYP0322 against standard chemotherapy for people with a specific type of advanced lung cancer (ROS1-positive non-small cell lung cancer) that has stopped responding to earlier targeted treatments. About 207 participants will be randomly assigned…

This study tests whether giving fecal transplants (from people who responded well to immunotherapy) to lung cancer patients can improve their response to standard treatment. About 68 adults with stage II-III non-small cell lung cancer will either get the transplant plus chemo and…

This early-stage study tests a new gene-editing drug called EDB-102 in 15 adults with advanced non-small cell lung cancer that has spread to the liver and is no longer responding to standard targeted therapy. The drug uses CRISPR technology to find and disable a specific cancer-c…

This early-phase study tests two drugs—navlimetostat and pumitamig—together in people with a certain genetic type of advanced non-small cell lung cancer (MTAP-deficient). The main goals are to find a safe dose and see if the combination shrinks tumors. About 17 adults with measur…

This study tests whether adding plinabulin to standard chemotherapy (docetaxel) helps people with advanced non-squamous lung cancer live longer. It includes about 442 adults whose cancer has worsened after prior immunotherapy and platinum chemo. Participants are randomly assigned…

This study tests a new combination of two drugs, HLX43 and serplulimab, in 120 people with advanced lung cancer that has spread or cannot be removed by surgery. The goal is to find the best dose and see if the treatment can shrink tumors. Participants must be between 18 and 75 ye…

This study tests a new medicine, PF-08634404, given alone or with chemotherapy for adults with early or locally advanced non-small cell lung cancer. The goal is to see if it can shrink tumors before surgery or prevent cancer from returning after treatment. About 120 participants …

This study looks at whether removing the main lung tumor before giving immunotherapy (sintilimab) and chemotherapy can help people with advanced non-small cell lung cancer live longer without the disease getting worse. About 118 adults aged 18-75 with a specific type of lung canc…

This phase 3 study tests whether a new drug (HS-20093) combined with an immunotherapy (adebrelimab) works better than standard chemotherapy (docetaxel) for people with advanced non-squamous non-small cell lung cancer that has already been treated. About 450 adults will be randoml…

This study looks at whether surgically removing the primary lung tumor before starting the targeted drug osimertinib can help people with advanced EGFR-mutant non-small cell lung cancer live longer without the disease getting worse. About 118 adults with stage III-IV cancer who h…

This early-stage trial tests a new drug called FXB0871 in adults with advanced solid tumors, including lung and liver cancers, that have not responded to standard treatments. The study aims to find the safest dose and check if the drug can shrink tumors. About 138 participants wi…

This phase II trial tests a treatment called GC101 TIL, which uses immune cells taken from a patient's own lung tumor. These cells are grown in a lab and then infused back into the patient to attack the cancer. The study involves 28 adults with non-small cell lung cancer who have…

This study tests whether adding a new drug (SYS6010) to the standard targeted therapy (osimertinib) before surgery can shrink tumors more effectively in people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer). About 120 adults with stage II to IIIB dis…

This early-phase trial tests a new drug called ITC-6146RO in about 102 adults with advanced or metastatic cancers (prostate, lung, breast, or other solid tumors) that have not responded to standard treatments. The study has two parts: first, finding the safest dose, then checking…

This study tests whether giving radiation to all brain tumors first, followed by a new immunotherapy drug (ivonescimab) plus chemotherapy, works better than starting with the drug and chemo alone. About 158 adults with non-small cell lung cancer that has spread to the brain but w…

This early-stage study tests a new drug called QLS5316 in about 300 people with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This study tests a new drug called SYS6010 against a standard chemotherapy (docetaxel) in people with a certain type of advanced lung cancer (non-squamous non-small cell) that no longer responds to standard treatments. About 506 adults will be randomly assigned to receive either …

This study tests whether a fecal microbiota transplant (FMT) combined with the drug tislelizumab can help people with advanced non-small cell lung cancer whose disease got worse after prior immunotherapy. The goal is to see if changing gut bacteria can restore the immune system's…

This study tests whether adding a new drug (recaticimab) to standard immunotherapy and chemotherapy before surgery can improve outcomes for people with resectable non-small cell lung cancer. About 78 adults with stage II to IIIB lung cancer will receive the combination treatment …

This early-stage study tests a new drug called IM-1617 in about 175 people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, finding the right dose, th…

This study tests two drugs together for people with advanced non-small cell lung cancer that has certain HER2 gene changes. The drugs aim to shrink tumors and slow the cancer's growth. About 30 adults aged 18-75 who have not responded to or have not yet had standard therapy will …

This early-phase study tests a new drug called CS08399 in people with advanced solid tumors or lymphoma that have a specific genetic deletion (MTAP). The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 186 adults who have run out of …

This study tests a new type of radiation therapy (Y-90 FAPI) in 10 adults with advanced non-small cell lung cancer that has stopped responding to standard treatments. The therapy targets a protein found on cancer cells to deliver radiation directly to tumors. The goal is to see i…

This early-stage study tests a combination of two drugs, izalontamab brengitecan and adagrasib, in 18 adults with advanced KRAS G12C lung cancer that has not responded to other treatments. The main goal is to check safety and see if the combo can work better than current options …

This study is for people with a type of lung cancer (EGFR-mutant NSCLC) that has spread to other parts of the body after they finished a targeted therapy called osimertinib. The goal is to see if giving osimertinib together with chemotherapy can help control the cancer for longer…

This study compares a new drug called YL202 to the standard chemotherapy docetaxel in people with advanced non-small cell lung cancer that has a specific EGFR mutation. Participants must have already tried an EGFR-targeted pill and platinum chemotherapy without success. The goal …

This study looks at whether a drug called Leucogen can prevent low white blood cell counts (leukopenia) in people with RET fusion-positive non-small cell lung cancer who are being treated with pralsetinib. The study will enroll 25 people who have not had prior treatment. Research…

This study tests a new drug called ANS02 in people with advanced non-small cell lung cancer that has a specific EGFR mutation. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 294 adults with good organ function and measur…

This study tests whether a targeted drug called divarasib can prevent lung cancer from coming back after surgery in people with a specific gene mutation (KRAS G12C). About 400 adults with stage II-III non-small cell lung cancer who had surgery and prior chemo-immunotherapy will r…

This study tests a combination of two experimental drugs, ABSK043 and glecirasib, in people with advanced non-small cell lung cancer that has a specific mutation called KRAS G12C. The goal is to see if the combination is safe and shrinks tumors. About 86 adults will take part in …

This study tests two different immunotherapy drug combinations (durvalumab plus either monalizumab or oleclumab) followed by personalized radiation for people with advanced non-small cell lung cancer that has a high level of a protein called PD-L1. The goal is to see which combin…

This study looks at whether a 12-week exercise program can improve how well immunotherapy works in people with non-small cell lung cancer. One hundred participants will either do moderate or high-intensity interval cycling, or receive standard exercise advice. Researchers will me…

This study tests a combination of two drugs, chidamide and ivonescimab, in 32 adults with advanced non-small cell lung cancer that has stopped responding to immunotherapy and has high levels of a protein called YAP. The goal is to see if the combo can shrink tumors or delay cance…

This study tests a new drug called SYS6090 combined with chemotherapy or other targeted drugs in people with advanced lung cancer that cannot be removed by surgery. The goal is to see if the combination is safe and helps shrink tumors. About 596 adults aged 18 to 75 with non-smal…

This study tests a combination of limertinib (a targeted pill) plus two chemotherapy drugs (carboplatin and etoposide) in 30 adults with a specific type of lung cancer. These patients had non-small cell lung cancer with an EGFR mutation, but after initial targeted therapy stopped…

This study tests whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TILs), can help prevent lung cancer from coming back after surgery. About 45 adults with a specific type of non-small cell lung cancer will receive either TILs or standard care. The main…

This study tests whether combining a targeted drug (furmonertinib) with local treatments like ablation or radiation can help control early-stage non-small cell lung cancer in people who cannot have surgery or choose not to. About 45 participants with specific EGFR gene mutations …

This study tests a new drug called SHR-1826 in 90 adults with advanced or metastatic non-small cell lung cancer that has worsened after other treatments. Participants receive the drug by IV every three weeks. The goal is to see if the drug shrinks tumors and to check its safety.

This study will observe 300 people with advanced solid tumors (like lung or gastrointestinal cancers) who receive adebrelimab combined with other treatments. The goal is to see how safe and effective these combinations are in everyday medical practice. Researchers will track side…

This study tests a drug called AK112 in 60 adults with advanced non-squamous non-small cell lung cancer who have specific genetic changes and whose previous targeted therapy (TKI) stopped working. The goal is to see if AK112 can shrink tumors or slow the disease. Participants mus…

This study tests a combination of two drugs (SHR-A1811 and pertuzumab) in 60 adults with advanced non-small cell lung cancer that has a specific change called HER2 alteration and has worsened after at least one prior treatment. The goal is to see if the combo can shrink tumors or…

This study tests whether giving the numbing drug lidocaine during lung cancer surgery can lower the chance of the cancer returning or spreading. About 1,400 adults having minimally invasive lung cancer surgery will be randomly assigned to receive lidocaine or a placebo. Researche…

This study tests a drug called TolueneSulfonamide, injected directly into the chest, to see if it safely reduces fluid buildup in people with lung cancer. About 105 adults with non-small cell lung cancer and trouble breathing will take part. The goal is to control the fluid and e…

This early-phase study tests a new daily pill, KQB368, in adults with advanced solid tumors (like lung, colon, or uterine cancer) that have a KRAS G12S or G12C mutation and no standard cure. The main goals are to find a safe dose and see if the drug can shrink tumors. About 48 pa…

This study looks at whether low-dose CT scans can help find lung cancer early in people aged 40 to 80 who have never smoked. Researchers will also test a new risk prediction model using questionnaires, blood, urine, and lung function tests. The goal is to improve screening for no…

This early study tests a new radioactive antibody (NTH-2403) that attaches to a protein found on certain cancer cells and their supporting cells. The goal is to see if it can safely light up tumors on scans in people with advanced colorectal, head and neck, lung, or triple-negati…

This study tests whether adding pentoxifylline and vitamin E to standard cancer treatment can prevent lung injury (pneumonitis) in 150 adults with stage III non-small cell lung cancer. Participants will receive the drugs alongside chemoradiation and immunotherapy. The goal is to …

This study looks at whether doing a simple exercise program for two weeks before non-small cell lung cancer surgery can help reduce pain, speed up recovery, and shorten hospital stays. About 62 adults scheduled for surgery will either do daily walking and breathing exercises or r…

This study tests whether a personalized exercise program is practical for people with stage II or III lung cancer before they start treatment. Twenty participants will follow the program, and researchers will track how many complete at least 80% of the sessions. The goal is to se…

This study tests a visual interactive chatbot on the LINE app to help people with advanced lung cancer manage side effects from targeted therapy (EGFR-TKIs). About 178 participants will either get usual care or also access the chatbot, which provides tips and tracking for symptom…

This study looks at whether adding electro-acupuncture to standard chemotherapy and immunotherapy can help people with advanced non-small cell lung cancer. About 424 participants will receive either real or sham acupuncture alongside their first few cycles of treatment. The main …

This study tests a new way to perform robotic lung surgery for early-stage non-small cell lung cancer. Surgeons will use 3D virtual reality models and a special dye (ICG) that glows under near-infrared light to see exactly which part of the lung to remove. The goal is to make the…

This study tests whether adding megestrol acetate (a drug that stimulates appetite) to standard cancer treatment helps malnourished patients with non-small cell lung cancer gain weight. About 116 adults with advanced lung cancer will be randomly assigned to receive either standar…

This study interviews about 85 lung cancer patients and 15 doctors in China to find out what makes it easier or harder for patients to keep taking the targeted therapy osimertinib after surgery. The goal is to identify barriers like side effects, cost, or communication issues, an…

This early study looks at whether adding febuxostat (a gout medicine) to the standard lung cancer drug osimertinib can increase how much of the cancer drug gets into the brain fluid. Only 7 patients with EGFR-mutated lung cancer and no brain metastases will take part. The goal is…

This study tests whether 3D models made from a standard CT scan (no contrast dye) are as accurate as contrast-enhanced CT scans for planning lung cancer surgery. About 50 adults with early-stage lung cancer will have both scans, and doctors will compare the 3D model's predictions…

This study looks at whether a blood test can find tiny bits of cancer DNA left after surgery for breast, lung, prostate, ovarian, or stomach cancer. About 840 adults who had their cancer removed will give blood samples over a year. The goal is to learn how often this DNA is found…

This study will collect tumor samples from 150 adults with non-small cell lung cancer (NSCLC) at all stages. Researchers will analyze the samples to understand the molecular, metabolic, and immune factors that drive cancer growth and return. The goal is to find patterns that coul…

This study looks at whether tiny particles in the blood, called extracellular vesicles, can help predict how well immunotherapy works for people with advanced lung cancer or melanoma. Researchers will collect blood samples from 378 patients before and during standard treatment. T…

This study tests a non-invasive device that delivers low-intensity electric fields (TTFields) to people with early-stage lung cancer before they have surgery. The main goal is to see how these fields affect certain cancer-related genes, not to cure the disease. About 18 participa…

This study looks at whether changes in certain immune cells in the blood can help predict how well chemotherapy combined with immunotherapy works for people with advanced non-small cell lung cancer. Researchers will take blood samples before and after the first two treatment cycl…